NO20033737D0 - PEG-konjugater av IIGT-NK4 - Google Patents

PEG-konjugater av IIGT-NK4

Info

Publication number
NO20033737D0
NO20033737D0 NO20033737A NO20033737A NO20033737D0 NO 20033737 D0 NO20033737 D0 NO 20033737D0 NO 20033737 A NO20033737 A NO 20033737A NO 20033737 A NO20033737 A NO 20033737A NO 20033737 D0 NO20033737 D0 NO 20033737D0
Authority
NO
Norway
Prior art keywords
iigt
peg conjugates
conjugates
peg
Prior art date
Application number
NO20033737A
Other languages
English (en)
Other versions
NO20033737L (no
Inventor
Michael Brandt
Apollon Papadimitriou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20033737D0 publication Critical patent/NO20033737D0/no
Publication of NO20033737L publication Critical patent/NO20033737L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20033737A 2001-02-23 2003-08-22 PEG-konjugater av HGT-NK4 NO20033737L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01104640A EP1234583A1 (en) 2001-02-23 2001-02-23 PEG-conjugates of HGF-NK4
PCT/EP2002/001837 WO2002074344A2 (en) 2001-02-23 2002-02-21 Peg-conjugates of hgt-nk4

Publications (2)

Publication Number Publication Date
NO20033737D0 true NO20033737D0 (no) 2003-08-22
NO20033737L NO20033737L (no) 2003-10-21

Family

ID=8176596

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033737A NO20033737L (no) 2001-02-23 2003-08-22 PEG-konjugater av HGT-NK4

Country Status (27)

Country Link
US (2) US20030012775A1 (no)
EP (2) EP1234583A1 (no)
JP (2) JP2004521139A (no)
KR (2) KR20090020713A (no)
CN (1) CN100339393C (no)
AR (1) AR032574A1 (no)
AU (1) AU2002233354B2 (no)
BG (1) BG108125A (no)
BR (1) BR0207510A (no)
CA (1) CA2438308A1 (no)
CZ (1) CZ20032511A3 (no)
EC (1) ECSP034741A (no)
GT (1) GT200200038A (no)
HR (1) HRP20030659A2 (no)
HU (1) HUP0400979A2 (no)
IL (1) IL157426A0 (no)
MA (1) MA26998A1 (no)
MX (1) MXPA03007130A (no)
NO (1) NO20033737L (no)
PA (1) PA8540501A1 (no)
PE (1) PE20020992A1 (no)
PL (1) PL367402A1 (no)
RU (1) RU2293574C2 (no)
SK (1) SK11652003A3 (no)
WO (1) WO2002074344A2 (no)
YU (1) YU65103A (no)
ZA (1) ZA200306080B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019991A2 (en) * 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
JP2007525425A (ja) * 2003-03-24 2007-09-06 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−２誘導体
WO2005095611A1 (en) * 2004-03-03 2005-10-13 F. Hoffmann-La Roche Ag Method for the recombinant expression of an n-terminal fragment of hepatocyte growth factor
EP1723171B1 (en) 2004-03-03 2007-12-19 F.Hoffmann-La Roche Ag Method for the purification of an n-terminal fragment of hepatocyte growth factor
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
CA2720611C (en) * 2008-04-09 2016-07-12 Viromed Co., Ltd. Lyophilized dna formulations for enhanced expression of plasmid dna
CN102399293B (zh) * 2008-06-03 2013-12-04 中国科学院遗传与发育生物学研究所 一种与纤维蛋白特异结合的重组蛋白及其应用
US10532020B2 (en) 2012-08-22 2020-01-14 Revlon Consumer Products Corporation Nail coatings having enhanced adhesion
JP2016519108A (ja) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０を疾病及び疾患の治療に用いる方法
WO2014204816A2 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
JP2017536098A (ja) 2014-10-14 2017-12-07 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１５組成物及びその使用
WO2016064817A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン１０の使用方法
WO2020158690A1 (ja) * 2019-01-28 2020-08-06 東レ株式会社 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体
WO2020158691A1 (ja) * 2019-01-28 2020-08-06 東レ株式会社 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2118012A1 (en) 1992-05-18 1993-11-25 Paul J. Godowski Hepatocyte growth factor variants
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
SK166695A3 (en) * 1994-03-31 1997-02-05 Amgen Inc Mgdf polypeptide for stimulating growth and megakaryocyte differentiation
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69631329T2 (de) * 1995-03-10 2004-11-18 Sumitomo Pharmaceuticals Co., Ltd. Menschlicher wachstumsfaktor (hgf), verändert durch polyethylenglykol
EP0741187A2 (en) * 1995-05-05 1996-11-06 F. Hoffmann-La Roche Ag Recombinant obese (Ob) proteins
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
EP1007082B1 (en) * 1997-01-15 2006-10-18 Phoenix Pharmacologics, Inc. Modified tumor necrosis factor
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
JP4574007B2 (ja) * 1998-04-28 2010-11-04 メルク・セローノ・ソシエテ・アノニム ポリオール−ｉｆｎ−ベータ複体
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
MXPA03005406A (es) * 2000-12-20 2003-09-25 Hoffmann La Roche Conjugados de eritropoyetina.

Also Published As

Publication number Publication date
PL367402A1 (en) 2005-02-21
ECSP034741A (es) 2003-10-28
MA26998A1 (fr) 2004-12-20
AR032574A1 (es) 2003-11-12
US20080085857A1 (en) 2008-04-10
CN1571679A (zh) 2005-01-26
RU2293574C2 (ru) 2007-02-20
CA2438308A1 (en) 2002-09-26
MXPA03007130A (es) 2003-11-18
BR0207510A (pt) 2004-07-27
US20030012775A1 (en) 2003-01-16
WO2002074344A3 (en) 2003-12-04
ZA200306080B (en) 2004-11-23
GT200200038A (es) 2002-09-30
JP2004521139A (ja) 2004-07-15
IL157426A0 (en) 2004-03-28
CZ20032511A3 (en) 2004-03-17
SK11652003A3 (sk) 2004-05-04
PE20020992A1 (es) 2002-11-01
RU2003127395A (ru) 2005-03-20
KR20030072629A (ko) 2003-09-15
US7846896B2 (en) 2010-12-07
KR20090020713A (ko) 2009-02-26
HRP20030659A2 (en) 2004-08-31
AU2002233354B2 (en) 2006-11-30
JP2010174034A (ja) 2010-08-12
PA8540501A1 (es) 2002-09-30
EP1389132A2 (en) 2004-02-18
EP1234583A1 (en) 2002-08-28
NO20033737L (no) 2003-10-21
CN100339393C (zh) 2007-09-26
WO2002074344A2 (en) 2002-09-26
HUP0400979A2 (hu) 2004-08-30
BG108125A (bg) 2004-09-30
YU65103A (sh) 2006-03-03

Similar Documents

Publication Publication Date Title
ATE553775T1 (de) Impstoffzusammesetzung
ATE319451T1 (de) Tetrahydrochinolin-derivate
ATE524462T1 (de) C5-modifizierte indazolylpyrrolotriazine
DE60116518D1 (de) Mehrzweckbohrwagen
EE200300416A (et) Ravimvorm
NO20033737D0 (no) PEG-konjugater av IIGT-NK4
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
NO20040125L (no) Enterale formuleringer
DE50208638D1 (de) Katheter
DK1427444T3 (da) West-nil-vaccine
ID30187A (id) Dongkrak jenis pantagraf
DE60214255D1 (de) Schlussstück
IS7051A (is) Lyfjasamsetningar
NO20033882L (no) Vaksine
DE50209410D1 (de) Kugelgelenk
IS2523B (is) Turn vindorkuvers
NO20041968L (no) Anvendelse av cystationin
EE200300480A (et) Pregabaliini-laktoosi konjugaadid
DE60216881D1 (de) Schlupfbegrenztes Differential
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
DE50200466D1 (de) Symmetrierübertrager
DE50201862D1 (de) Messwandler
DE60129205D1 (de) Mittelspannungskabelendverschluss
NO20035742D0 (no) Kjemisk modifisert progenipoietin konjugater
DE10107471B4 (de) Vitrine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application